

Catharina C Gross

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4728464/publications.pdf>

Version: 2024-02-01

55
papers

2,254
citations

257450

24
h-index

233421

45
g-index

57
all docs

57
docs citations

57
times ranked

3979
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural Killer Cells Are Present in Rag1 ^{Δ6} /Δ6 Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke. <i>Translational Stroke Research</i> , 2022, 13, 197-211.	4.2	10
2	High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1491-1496.	3.0	5
3	Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. <i>Brain Communications</i> , 2021, 3, fcab157.	3.3	25
4	Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity. <i>Brain</i> , 2021, 144, 1152-1166.	7.6	28
5	Classification of neurological diseases using multi-dimensional CSF analysis. <i>Brain</i> , 2021, 144, 2625-2634.	7.6	22
6	The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome. <i>Journal of Clinical Immunology</i> , 2021, 41, 1229-1240.	3.8	5
7	Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype. <i>Annals of Neurology</i> , 2021, 90, 118-129.	5.3	10
8	Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2021, 17, 433-447.	10.1	9
9	Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. <i>Molecular Psychiatry</i> , 2021, 26, 7661-7670.	7.9	18
10	Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 91, 233-243.	2.0	8
11	Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies. <i>Epilepsia</i> , 2020, 61, e153-e158.	5.1	12
12	Immune signatures of prodromal multiple sclerosis in monozygotic twins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21546-21556.	7.1	36
13	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. <i>Nature Communications</i> , 2020, 11, 247.	12.8	242
14	Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 341, 577171.	2.3	17
15	Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study. <i>EBioMedicine</i> , 2019, 46, 381-386.	6.1	14
16	Impact of Fcγ3R variants on the response to alemtuzumab in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2586-2594.	3.7	4
17	Human CCR5 ^{high} effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. <i>Brain</i> , 2019, 142, 3411-3427.	7.6	39
18	Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke. <i>European Journal of Neurology</i> , 2019, 26, 919-926.	3.3	10

#	ARTICLE	IF	CITATIONS
19	Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies. <i>Frontiers in Immunology</i> , 2019, 10, 515.	4.8	26
20	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	92
21	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. <i>BMJ Open</i> , 2019, 9, e030309.	1.9	63
22	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019, 10, 5779.	12.8	87
23	Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 271-276.	7.1	40
24	Sex bias in MHC I-associated shaping of the adaptive immune system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2168-2173.	7.1	51
25	Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. <i>Multiple Sclerosis Journal</i> , 2018, 24, 563-573.	3.0	28
26	Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 62, 45-52.	3.1	6
27	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1081.	2.4	91
28	Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis. <i>Frontiers in Neurology</i> , 2018, 9, 658.	2.4	8
29	Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study. <i>Frontiers in Immunology</i> , 2018, 9, 1560.	4.8	24
30	Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System. <i>Frontiers in Neurology</i> , 2018, 9, 407.	2.4	13
31	Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy034.	0.4	3
32	Immune cell profiling in the cerebrospinal fluid of patients with primary angiitis of the central nervous system reflects the heterogeneity of the disease. <i>Journal of Neuroimmunology</i> , 2018, 321, 109-116.	2.3	16
33	Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1871-1882.	3.0	21
34	Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E908-E909.	7.1	3
35	Analysis of Lymphocyte Extravasation Using an <i>In Vitro</i> Model of the Human Blood-brain Barrier. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	3
36	Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1025-1030.	3.0	30

#	ARTICLE	IF	CITATIONS
37	Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab. Oxford Medical Case Reports, 2017, 2017, omx034.	0.4	4
38	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology, 2017, 4, 768-783.	3.7	101
39	An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function. Frontiers in Neurology, 2017, 8, 517.	2.4	5
40	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 606.	4.8	88
41	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2973-82.	7.1	157
42	B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6182-E6191.	7.1	24
43	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Science Translational Medicine, 2016, 8, 364ra152.	12.4	94
44	Prothrombin and factor X are elevated in multiple sclerosis patients. Annals of Neurology, 2016, 80, 946-951.	5.3	35
45	Fingolimod treatment promotes regulatory phenotype and function of B cells. Annals of Clinical and Translational Neurology, 2015, 2, 119-130.	3.7	82
46	The two-pore domain K ⁺ channel TASK2 drives human NK cell proliferation and cytolytic function. European Journal of Immunology, 2015, 45, 2602-2614.	2.9	12
47	Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells. International Journal of Molecular Sciences, 2015, 16, 16330-16346.	4.1	25
48	Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Frontiers in Neurology, 2015, 6, 167.	2.4	26
49	Neurocognitive decline in HIV patients is associated with ongoing T cell activation in the cerebrospinal fluid. Annals of Clinical and Translational Neurology, 2015, 2, 906-919.	3.7	40
50	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. Journal of Immunology, 2015, 195, 3584-3595.	0.8	13
51	Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC Neurology, 2015, 15, 96.	1.8	7
52	Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiology of Aging, 2015, 36, 81-89.	3.1	141
53	Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking. PLoS ONE, 2014, 9, e115920.	2.5	43
54	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. Journal of Experimental Medicine, 2014, 211, 1833-1846.	8.5	134

#	ARTICLE	IF	CITATIONS
55	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Annals of Neurology, 2014, 75, 739-758.	5.3	100